Zenocutuzumab is a Monoclonal Antibody owned by Merus, and is involved in 4 clinical trials, which are ongoing.

Zenocutuzumab is a bi-specific monoclonal antibody (MCLA-128) targets human epidermal growth factor receptor 2 and 3. The therapeutic candidate inhibits the HER-2 and HER-3 family receptor activation and controls the cancer. MCLA-128 kills HER2-overexpressing tumor cells using two mechanisms, by blocking the growth and survival pathways to stop tumor expansion while preventing treatment escape through the HER3/heregulin axis and by efficient recruitment of immune effector cells to directly lyse the tumor.

The revenue for Zenocutuzumab is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zenocutuzumab NPV Report.

Zenocutuzumab is originated and owned by Merus.

Zenocutuzumab Overview

Zenocutuzumab (MCLA-128) is under development for the treatment of solid tumors, HER2 low expressing and HER2 positive metastatic breast cancer, pancreatic cancer, non-small cell lung cancer, Cholangiocarcinoma, metastati castration resistant prostate cancer and other solid tumors. It is administered by intravenous route as an infusion. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, that is developed based on Biclonics ENGAGE platform.

It was also under development for the treatment of ovarian cancer, metastatic colorectal cancer, epithelial tumor, gastric cancer, endometrial cancer, pancreatic ductal adenocarcinoma.

Merus Overview

Merus is a pharmaceutical company that discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; ONO-4685, for the treatment of autoimmune disease. It is also evaluating MCLA-158 and MCLA-129, to treat solid tumors and MCLA-145, a T-cell agonist targeting hematological malignancy and solid tumors. Merus utilizes Multiclonics, Biclonics and Triclonics technology platform for developing antibodies to treat cancer. The company works in collaboration with Incyte Corporation, Simcere Pharmaceutical Group, Ono Pharmaceutical Co., Ltd. and Betta Pharmaceuticals Co Ltd to advance its pipeline products. Merus is headquartered in Utrecht, the Netherlands.

The company reported revenues of (US Dollars) US$49.1 million for the fiscal year ended December 2021 (FY2021), an increase of 64% over FY2020. The operating loss of the company was US$90 million in FY2021, compared to an operating loss of US$75.9 million in FY2020. The net loss of the company was US$66.8 million in FY2021, compared to a net loss of US$85.5 million in FY2020. The company reported revenues of US$6.6 million for the third quarter ended September 2022, a decrease of 48.1% over the previous quarter.

Quick View – Zenocutuzumab

Report Segments
  • Innovator
Drug Name
  • Zenocutuzumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.